Leszek Zaremba

Leszek Zaremba is a Managing Partner at Leonarto, a Wrocław-based early-stage venture capital fund founded in 2015 that backs technology and life-sciences companies. Within the Leonarto structure he served as an executive of the fund's investment vehicle Leonarto Alfa: he was Deputy CEO before being appointed CEO of Leonarto Alfa S.A. around October–November 2018, succeeding Cezary Wojciech Iwan. His firm email address ([hidden]) confirms his ongoing affiliation with the fund.

Zaremba's professional identity is rooted in R&D and innovation management rather than pure finance. His LinkedIn headline describes him as "experienced in R&D and Innovation Management, building of innovation ecosystem," and he is associated with Innovation As A Service sp. z o.o. He studied at the Technical University of Wrocław (Politechnika Wrocławska, 2002–2007), with further studies through 2008–2010, and has been a member of the International Project Management Association (IPMA) since 2010. His stated areas of expertise include innovation ecosystem development, project management, Lean methodologies, and "management by values."

Beyond investing, he has an academic/practitioner publishing record, with works on management by values in the mining sector, Lean implementation at KGHM Polska Miedź, and knowledge transfer between science and business — reflecting the deep-tech, science-to-market orientation that characterizes Leonarto's portfolio.

• Invests at seed / early stage in Polish deep-tech and life-sciences companies with a strong R&D and intellectual-property foundation.
• Leonarto's four stated selection criteria are: a breakthrough project (disruptive potential), market demand, a strong team ("determined, committed founders who are experts in their fields"), and global scaling potential.
• Emphasis on IP protection — the fund actively supports international patent applications as part of its diligence and value-add.
• Provides "smart money": hands-on involvement in R&D, IP strategy, follow-on fundraising, and partnership/business development rather than passive capital.
• Sector appetite spans nanotechnology, biotech/medtech, telemedicine, molecular biology, space, fintech, HR-tech, and AI/deep learning.
• Track record framed around achieving successful capital exits with above-average rates of return.